195 related articles for article (PubMed ID: 33392498)
1. A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery.
Maturavongsadit P; Paravyan G; Kovarova M; Garcia JV; Benhabbour SR
Int J Pharm X; 2021 Dec; 3():100068. PubMed ID: 33392498
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.
Maturavongsadit P; Shrivastava R; Sykes C; Cottrell ML; Montgomery SA; Kashuba ADM; Rahima Benhabbour S
Int J Pharm; 2021 Aug; 605():120844. PubMed ID: 34216767
[TBL] [Abstract][Full Text] [Related]
3. Effect of implant formation on drug release kinetics of in situ forming implants.
Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
[TBL] [Abstract][Full Text] [Related]
4. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
[TBL] [Abstract][Full Text] [Related]
5. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
6. Effects of Drug Physicochemical Properties on In-Situ Forming Implant Polymer Degradation and Drug Release Kinetics.
Joiner JB; Prasher A; Young IC; Kim J; Shrivastava R; Maturavongsadit P; Benhabbour SR
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745761
[TBL] [Abstract][Full Text] [Related]
7. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
8. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
9. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
10. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations.
Khuroo T; Dharani S; Mohamed EM; Immadi S; Wu Z; Khan MA; Lu D; Nehete P; Rahman Z
Int J Pharm; 2021 Sep; 607():120889. PubMed ID: 34271151
[TBL] [Abstract][Full Text] [Related]
11. Review: approaches to develop PLGA based in situ gelling system with low initial burst.
Ahmed T
Pak J Pharm Sci; 2015 Mar; 28(2):657-65. PubMed ID: 25730797
[TBL] [Abstract][Full Text] [Related]
12. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
[TBL] [Abstract][Full Text] [Related]
13. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
Dong WY; Körber M; López Esguerra V; Bodmeier R
J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
[TBL] [Abstract][Full Text] [Related]
14. In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery.
Khuroo T; Mohamed EM; Dharani S; Immadi S; Nutan MTH; Lu D; Ali HI; Khan MA; Rahman Z
J Pharm Sci; 2022 Aug; 111(8):2312-2321. PubMed ID: 35296412
[TBL] [Abstract][Full Text] [Related]
15. Hot Melt Extrusion for Sustained Protein Release: Matrix Erosion and In Vitro Release of PLGA-Based Implants.
Cossé A; König C; Lamprecht A; Wagner KG
AAPS PharmSciTech; 2017 Jan; 18(1):15-26. PubMed ID: 27193002
[TBL] [Abstract][Full Text] [Related]
16. Burst Release from In Situ Forming PLGA-Based Implants: 12 Effectors and Ways of Correction.
Bakhrushina EO; Sakharova PS; Konogorova PD; Pyzhov VS; Kosenkova SI; Bardakov AI; Zubareva IM; Krasnyuk II; Krasnyuk II
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258125
[TBL] [Abstract][Full Text] [Related]
17. Development of implants for sustained release of 5-fluorouracil using low molecular weight biodegradable polymers.
Hanafy AF; El-Egaky AM; Mortada SA; Molokhia AM
Drug Discov Ther; 2009 Dec; 3(6):287-95. PubMed ID: 22495663
[TBL] [Abstract][Full Text] [Related]
18. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
19. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery.
Benhabbour SR; Kovarova M; Jones C; Copeland DJ; Shrivastava R; Swanson MD; Sykes C; Ho PT; Cottrell ML; Sridharan A; Fix SM; Thayer O; Long JM; Hazuda DJ; Dayton PA; Mumper RJ; Kashuba ADM; Victor Garcia J
Nat Commun; 2019 Sep; 10(1):4324. PubMed ID: 31541085
[TBL] [Abstract][Full Text] [Related]
20. Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics.
Joiner JB; King JL; Shrivastava R; Howard SA; Cottrell ML; Kashuba ADM; Dayton PA; Benhabbour SR
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
